Skip to main content

Table 1 Baseline demographics and phenotypes in the investigated TAM-treated breast cancer patients (n = 40). Data are reported as the mean and 95% CI or percent

From: Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients

 Pre-menopausal
(n = 20)
Post-menopausal
(n = 20)
Age at diagnosis (years)45.3 (44.70–45.90)66.8 (66.13–67.46)
BMI (kg/m2)29.58 (28.90–30.25)28.07 (27.58–28.56)
Color (%)white (85), non-white (15)white (75), non-white (25)
Cancer type (%)ductal in situ (5), invasive ductal (90) and invasive lobular (5)ductal in situ (0), invasive ductal (90) and invasive lobular (10)
HER2 status (%)positive (20), negative (75) and unknown (5)positive (10), negative (80) and unknown (10)
Chemotherapy (%)Yes (20) and No (80)Yes (5) and No (95)
CYP2D6 phenotype (MR)0.25 (0.21–0.30)0.24 (0.19–0.29)
Midazolam oral clearance (mL/min/kg)30.09 (21.55–42.02)24.10 (19.41–29.92)
  1. MR Metabolic ratio (plasma log metoprolol/α-hydroxymetoprolol)